

# The social dimension of medicines

## Learning Objectives

In this module the students are expected to:

1. Identify and assess the relationship between global consumption of medicines and prevalence of diseases
  - 1.1. Identify the most used medicines globally
  - 1.2. Assess the regional differences in drug consumption
  - 1.3. Identify the global diseases prevalence
  - 1.4. Assess the regional differences in the disease prevalence
  - 1.5. Relate the regional differences between drug consumption and diseases prevalence
  
2. Review which factors determine the selection of the therapeutic area in the development of medicines
  - 2.1. Identify the therapeutic areas and the diseases for which drugs have been developed in the last decade
  - 2.2. Describe the main characteristics of the diseases for which drugs have been developed in the last decade
  - 2.3. Explain which factors determine the selection of the therapeutic area in the development of medicines
  - 2.4. Review the concepts of orphan drug and orphan disease
  
3. Identify promotional strategies from drug development to drug marketing
  - 3.1. Recognize the concept of disease mongering and its interest in the drug development and drug consumption
  - 3.2. Identify and define the main characteristics of the different commercial sources of information on medicines
  
4. Discuss the consequences of the criteria to authorize drugs in the European Union
  - 4.1. Describe the criteria to authorize medicines in Europe and its effects on the market of medicines
  - 4.2. Describe the therapeutic innovation concept
  - 4.3. Examine the therapeutic innovation level of drugs recently marketed
  - 4.4. Recognize the meaning of the WHO essential drugs list
  
5. Identify the need to have open access to the information gathered on the effects of medicines
  - 5.1. Identify the accessibility to the premarketing clinical trials results in the main regulatory agencies

5.2. Describe the concept of publication bias and its impact on the public knowledge regarding the efficacy and safety of drugs marketed

**ECTS Credits**

5

**Coordinators**

D Capellà, X Castells